Radioiodinated acemetacin loaded niosomes as a dual anticancer therapy

Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer

“…Vesicles also dispersed closely at a size of 200 nm, indicating that the particle production factors effectively produced an aggregated and spherical structure. 78 2.3.3. Microfluidization method.…”

Niosomes as a Novel Pharmaceutical Carrier: Structure, Classification and Preparation Methods

“…In this technique, surfactant with another additive (Cholesterol) is dispersed in diethyl ether and then injected in an aqueous solvent with a 14-gauge needle at a temperature above 60 °C. A rotatory evaporator must be used to completely evaporate the organic solvent; while ether evaporates slowly, surfactant aggregates to form vesicles with singlelayered (Nishu, Karmoker et al 2018, Kulkarni, Rawtani et al 2021, Shewaiter, Selim et al 2022.…”

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

“…Other new approaches evaluated the use of nanocarriers in radioisotope delivery for cancer diagnosis and therapy (Jalilian et al 2022 ). A new publication discussed the optimization of radioiodinated acemetacin-loaded niosomes for cancer therapy (Shewaiter et al 2022 ). The team used a D-optimal design to investigate the effects of independent variables such as cholesterol amount, span 60 amount, and hydration time on the dependent variables.…”

“…The stability study, particle size, zeta potential, and entrapment efficiency remained stable throughout the study. The in vivo pharmacokinetic differences in mice models, involving evaluation of C max , T max , T 1/2 , MRT, AUC 0–24 , tumor AUC 0–24 , and the tumor drug targeting efficiency (AUC target/AUC non-target), indicated higher drug accumulation in the tumor compared to the blood and other body organs (Shewaiter et al 2022 ). Overall, the report showed that niosomal formula increased tumor uptake of radioiodinated acemetacin by passive targeting of the nanosized niosomes with a possibility of combining the chemotherapeutic effect of acemetacin and radiotherapeutic effect of 131 I in one therapeutic agent.…”